Product
Recombinant Zoster Vaccine
6 clinical trials
4 indications
Indication
Herpes ZosterIndication
Varicella ZosterIndication
RZV Vaccine (Shingrix)Indication
Herpes zosterClinical trial
A Phase I, Randomized, Observer Blind Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Zoster Vaccine (Adenovirus Vector) in Healthy Adults Aged 50-65 YearsStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase I, Randomized, Observer-blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV211 in Adult VolunteersStatus: Not yet recruiting, Estimated PCD: 2024-01-31
Clinical trial
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and AboveStatus: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant RecipientsStatus: Not yet recruiting, Estimated PCD: 2027-03-31
Clinical trial
Immune Response to the Recombinant Zoster Vaccine in People Living With HIV Over 50 Years of Age Compared to Non-HIV Age- and Gender-matched Controls - The Shingr'HIV Phase IV Multicenter StudyStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Immunogenicity of the Recombinant Zoster Vaccine (Shingrix ®) in Multiple Sclerosis Patients Treated With Anti-CD20 Antibodies Compared to Controls- a Phase IV Monocentric StudyStatus: Recruiting, Estimated PCD: 2024-12-31